- Home
- WHG vs CLLS Comparison
WHG vs CLLS Comparison
Compare WHG & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHG
- CLLS
- Stock Information
- Founded
- WHG 1983
- CLLS 1999
- Country
- WHG United States
- CLLS France
- Employees
- WHG N/A
- CLLS N/A
- Industry
- WHG Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- WHG Finance
- CLLS Health Care
- Exchange
- WHG Nasdaq
- CLLS Nasdaq
- Market Cap
- WHG 151.0M
- CLLS 143.4M
- IPO Year
- WHG 2002
- CLLS 2007
- Fundamental
- Price
- WHG $16.50
- CLLS $1.83
- Analyst Decision
- WHG
- CLLS Buy
- Analyst Count
- WHG 0
- CLLS 1
- Target Price
- WHG N/A
- CLLS $4.00
- AVG Volume (30 Days)
- WHG 72.8K
- CLLS 128.3K
- Earning Date
- WHG 07-30-2025
- CLLS 08-05-2025
- Dividend Yield
- WHG 3.76%
- CLLS N/A
- EPS Growth
- WHG N/A
- CLLS N/A
- EPS
- WHG 0.04
- CLLS N/A
- Revenue
- WHG $95,241,000.00
- CLLS $54,747,000.00
- Revenue This Year
- WHG N/A
- CLLS $48.52
- Revenue Next Year
- WHG N/A
- CLLS $5.17
- P/E Ratio
- WHG $340.29
- CLLS N/A
- Revenue Growth
- WHG 6.08
- CLLS 351.26
- 52 Week Low
- WHG $11.11
- CLLS $1.10
- 52 Week High
- WHG $18.03
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- WHG 56.64
- CLLS 60.54
- Support Level
- WHG $15.30
- CLLS $1.85
- Resistance Level
- WHG $16.85
- CLLS $2.36
- Average True Range (ATR)
- WHG 0.69
- CLLS 0.16
- MACD
- WHG 0.01
- CLLS 0.04
- Stochastic Oscillator
- WHG 77.33
- CLLS 48.06
About WHG Westwood Holdings Group Inc
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.